Skip to main content
Kleber Fertrin, MD, Hematology, Seattle, WA

KleberFertrinMDPhD

Hematology Seattle, WA

Blood Banking & Transfusion Medicine, Sickle Cell & Other Anemias

Assistant Professor

Dr. Fertrin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Fertrin's full profile

Already have an account?

  • Office

    825 Eastlake Avenue East
    MS LG-700
    Seattle, WA 98109
    Phone+1 206-606-2045
    Fax+1 206-606-1130

Summary

  • Dr. Kleber Fertrin is a hematologist specialized in Classical Hematology in Seattle, WA with an extensive background in Molecular Biology, Transfusion and Laboratory Medicine. His main clinical and research interests are hemolytic anemias, particularly sickle cell disease, thalassemias, iron overload, hemochromatosis, and rare diseases, such as pyruvate kinase deficiency, and variant hemoglobins.

Education & Training

  • NIH Clinical Center
    NIH Clinical CenterPost-Doctoral Fellowship, 2013 - 2014
  • University of Campinas Faculty of Medicine
    University of Campinas Faculty of MedicineClass of 2003

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2018 - 2025

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Abnormal Cytokine Production By Mast Cell Cultures from Sickle Cell Anemia Patients in Response to Inflammatory Stimuli and to Co-Culture with Eosinophils
    Kleber Yotsumoto Fertrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Safe Use of Hydroxyurea in Sickle Cell Disease Patients Hospitalized for Painful Vaso-Occlusive Episodes: Results of the Randomized, Open-Label Helps Study
    Kleber Yotsumoto Fertrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Blood Clots and Cancer
    Blood Clots and CancerSeptember 20th, 2023
  • FDA Approves Gene Editing Technology to Treat Sickle Cell Disease: HealthLink
    FDA Approves Gene Editing Technology to Treat Sickle Cell Disease: HealthLinkJanuary 7th, 2024

Professional Memberships

Other Languages

  • Portuguese, German